The Dr. Goodenowe
Neuro Summit
A full day dedicated to restoring
neurological health across the lifespan
April 18, 2026 | In-Person + Live Stream Event
The Dr. Goodenowe Neuro Summit
A full day dedicated to restoring
neurological health across the lifespan
March 18 @ 5 pm PST | Live Webinar
To achieve health and vitality, you must reprogram yourself to focus on the achievement of health, not the avoidance of disease
LATEST
From published research to investigational development.
In 2005, Dr. Goodenowe’s research identified plasmalogen deficiency as a consistent biochemical feature observed in Alzheimer’s disease. The findings were published in the Journal of Lipid Research in 2007 and have since been independently replicated across multiple research groups in Japan, Europe, and North America.
That body of research is the scientific foundation for Dr. Goodenowe Dietary Therapeutics (DGDT), a therapeutic development company currently advancing ProdromeNeuro™ — a plasmalogen precursor compound — through FDA-regulated pathways for the investigation of Alzheimer’s disease and related neurological conditions.
Breaking Alzheimer's
Dr. Goodenowe's account of his research into plasmalogen biochemistry and its observed relationship to neurodegeneration — written for a general audience.
Dr. Goodenowe Dietary Therapeutics
A therapeutic development company advancing plasmalogen-based compounds through FDA-regulated investigational pathways. Lead candidate: ProdromeNeuro™.
Breaking Alzheimer’s (2021) documents the research journey behind this work. ProdromeNeuro™ is an investigational compound. It is not approved by the FDA and is not intended to diagnose, treat, cure, or prevent any disease.
Our mission is to restore and optimize health by addressing the root causes of disease and enhancing overall well-being.
Our Programs
Biochemical testing, imaging and supplementation for longevity and vitality.
Where Science Supports Care
Medical professionals across disciplines are using Dr. Goodenowe’s tools – from advanced biochemistry testing to targeted protocols – to guide and enhance patient care.